Cargando…
Medical treatment options for COVID-19
Therapeutic options for coronavirus disease 2019 are desperately needed to respond to the ongoing severe acute respiratory syndrome coronavirus 2 pandemic. Both antiviral drugs and immunomodulators might have their place in the management of coronavirus disease 2019. Unfortunately, no drugs have bee...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7235633/ https://www.ncbi.nlm.nih.gov/pubmed/32363880 http://dx.doi.org/10.1177/2048872620922790 |
_version_ | 1783536000172032000 |
---|---|
author | Delang, Leen Neyts, Johan |
author_facet | Delang, Leen Neyts, Johan |
author_sort | Delang, Leen |
collection | PubMed |
description | Therapeutic options for coronavirus disease 2019 are desperately needed to respond to the ongoing severe acute respiratory syndrome coronavirus 2 pandemic. Both antiviral drugs and immunomodulators might have their place in the management of coronavirus disease 2019. Unfortunately, no drugs have been approved yet to treat infections with human coronaviruses. As it will take years to develop new therapies for severe acute respiratory syndrome coronavirus 2, the current focus is on the repurposing of drugs that have been approved or are in development for other conditions. Several clinical trials have already been conducted or are currently ongoing to evaluate the efficacy of such drugs. Here, we discuss the potential of these therapies for the treatment of coronavirus disease 2019. |
format | Online Article Text |
id | pubmed-7235633 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-72356332020-05-20 Medical treatment options for COVID-19 Delang, Leen Neyts, Johan Eur Heart J Acute Cardiovasc Care Reviews Therapeutic options for coronavirus disease 2019 are desperately needed to respond to the ongoing severe acute respiratory syndrome coronavirus 2 pandemic. Both antiviral drugs and immunomodulators might have their place in the management of coronavirus disease 2019. Unfortunately, no drugs have been approved yet to treat infections with human coronaviruses. As it will take years to develop new therapies for severe acute respiratory syndrome coronavirus 2, the current focus is on the repurposing of drugs that have been approved or are in development for other conditions. Several clinical trials have already been conducted or are currently ongoing to evaluate the efficacy of such drugs. Here, we discuss the potential of these therapies for the treatment of coronavirus disease 2019. Oxford University Press 2020-04-01 /pmc/articles/PMC7235633/ /pubmed/32363880 http://dx.doi.org/10.1177/2048872620922790 Text en © The European Society of Cardiology 2020 http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial reuse, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Reviews Delang, Leen Neyts, Johan Medical treatment options for COVID-19 |
title | Medical treatment options for COVID-19 |
title_full | Medical treatment options for COVID-19 |
title_fullStr | Medical treatment options for COVID-19 |
title_full_unstemmed | Medical treatment options for COVID-19 |
title_short | Medical treatment options for COVID-19 |
title_sort | medical treatment options for covid-19 |
topic | Reviews |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7235633/ https://www.ncbi.nlm.nih.gov/pubmed/32363880 http://dx.doi.org/10.1177/2048872620922790 |
work_keys_str_mv | AT delangleen medicaltreatmentoptionsforcovid19 AT neytsjohan medicaltreatmentoptionsforcovid19 |